After securing rights to a compound developed by Innate Pharma SA in 2011, Bristol-Myers Squibb Company (BMS) has expanded its investment in innate immunity with the purchase of IFM Therapeutics Inc of Boston, Massachusetts. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
